共 6 条
- [1] Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational studyJOURNAL OF NEUROLOGY, 2018, 265 (07) : 1521 - 1527Huhn, KonstantinBayas, AntoniosDoerck, SebastianFrank, BenediktGerbershagen, KathrinHellwig, KerstinKallmann, BorisKleinschnitz, ChristophKleiter, IngoLee, De-HyungLimmroth, VolkerMaeurer, MathiasMeuth, SvenRieckmann, PeterRuck, TobiasGold, RalfLinker, Ralf A.
- [2] Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational studyJournal of Neurology, 2018, 265 : 1521 - 1527Konstantin HuhnAntonios BayasSebastian DoerckBenedikt FrankKathrin GerbershagenKerstin HellwigBoris KallmannChristoph KleinschnitzIngo KleiterDe-Hyung LeeVolker LimmrothMathias MäurerSven MeuthPeter RieckmannTobias RuckRalf GoldRalf A. Linker
- [3] The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective StudyAdvances in Therapy, 2020, 37 : 2999 - 3009Florian LenzLutz Harms
- [5] The effect of glatiramer acetate (copaxone®) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS):: A multi-center, randomized, double blind, placebo-controlled study extended by open-label treatmentNEUROLOGY, 1999, 52 (06) : A289 - A289Comi, GFilippi, M
- [6] The effect of two doses of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multi-center randomized, double-blind, placebo-controlled studyNEUROLOGY, 2007, 68 (12) : A84 - A84Comi, GiancarloAbramsky, OdedArbizu, TxominBoiko, AlexeiGold, RalfHavrdova, EvaKomoly, SamuelSelmaj, Krzysztof W.Sharrack, BasilFilippi, Massimo